Abstract
AbstractChlorambucil is a classic nitrogen mustard drug that has been used in the treatment of cancers. It may induce neutropenia, thrombocytopenia and other side effects because of its short lifetime and off‐target effect. In this report, chlorambucil‐tetrapeptide (AAAK, A3K) conjugate vesicles were developed to improve the stability and bioactivity of chlorambucil. First of all, chlorambucil‐A3K conjugate was synthesized by solid phase synthesis strategy. Secondly, the chlorambucil‐A3K conjugate was assembled and characterized by critical aggregation concentration, circular dichroism, dynamic light scattering and transmission electron microscopy. The results indicated that the chlorambucil‐A3K conjugate can be assembled to form spherical vesicles with an average diameter of 390.5 nm, and high drug loading about 47.1% is reached. Surprisingly, the preliminary biological evaluation of the chlorambucil‐A3K conjugate vesicles revealed the best in vitro anticancer activity against HeLa, HepG‐2 and MCF‐7 cell lines compared with chlorambucil and chlorambucil‐A3K conjugate free drugs. Furthermore, conjugate vesicles showed excellent in vivo antitumoral activity. It can be partly attributed to their vesicular structure which isolates chlorambucil active moiety from aqueous solution to retard degradation before killing cancer cells. Therefore, chlorambucil‐peptide (A3K) conjugate vesicles may be an alternative delivery system of chlorambucil.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
